公开(公告)号：US20220119531A1

公开(公告)日：2022-04-21

申请号：US17563502

申请日：2021-12-28

Applicant: I-Mab Biopharma US Limited

Inventor： Lei Fang ,  Yongqiang Wang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

公开(公告)号：US11034771B2

公开(公告)日：2021-06-15

申请号：US16963091

申请日：2019-07-25

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang ,  Qiumei Yang

IPC: C07K16/28

Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.

公开(公告)号：US20200332005A1

公开(公告)日：2020-10-22

申请号：US16785953

申请日：2020-02-10

Applicant: I-MAB Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K9/06 ,  A61K35/17 ,  A61K39/395 ,  C07K16/40 ,  G01N33/574

Abstract: Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.